Aerovate Therapeutics Inc (AVTE)
$22.5
Insights on Aerovate Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 44.3% return, outperforming this stock by 14.2%
Performance
- $21.81$23.97$22.50
3.07%
Downside
Day's Volatility :9.01%
Upside
6.13%
- $9.41$32.42$22.50
58.18%
Downside
52 Weeks Volatility :70.97%
Upside
30.6%
Returns
| Period | Aerovate Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 17.1% | -0.5% | 0.0% |
6 Months | 109.96% | 5.9% | 0.0% |
1 Year | 30.14% | 3.1% | -1.9% |
3 Years | 57.05% | 14.2% | -21.8% |
Highlights
Market Capitalization | 695.7M |
Book Value | $3.94 |
Earnings Per Share (EPS) | -2.87 |
Wall Street Target Price | 44.67 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -38.73% |
Return On Equity TTM | -63.95% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -81.3M |
Diluted Eps TTM | -2.87 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.02 |
EPS Estimate Next Year | -2.96 |
EPS Estimate Current Quarter | -0.71 |
EPS Estimate Next Quarter | -0.68 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 98.53%
Technicals Summary
Sell
Neutral
Buy
Aerovate Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aerovate Therapeutics Inc | -10.5% | 109.96% | 30.14% | 57.05% | 57.05% |
 Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
 Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
 Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
 Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aerovate Therapeutics Inc | 0.88 | NA | NA | -3.02 | -0.64 | -0.39 | NA | 3.94 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aerovate Therapeutics Inc | Buy | $695.7M | 57.05% | 0.88 | 0.0% |
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
Institutional Holdings
RA Capital Management, LLC
29.66%Sofinnova Ventures
13.49%TCG Crossover Management, LLC
7.90%Baker Bros Advisors LP
6.03%Cormorant Asset Management, LLC
4.35%Driehaus Capital Management LLC
3.80%
Company Information
aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.
Organization | Aerovate Therapeutics Inc |
Employees | 51 |
CEO | Mr. Timothy P. Noyes M.B.A. |
Industry | Healthcare |
